Market reactionShares fell 13% on Nov 5.
Gain Therapeutics is a clinical-stage company developing rexaceract, an oral drug for Parkinson's disease that is not yet approved.
Gain's rexaceract, an oral drug that boosts the GCase enzyme in Parkinson's disease, kept motor scores stable over 12 months in 12 evaluable participants in a Phase 1b extension, an early signal rather than proof of efficacy. A Phase 2 trial is now planned for Q1 2027, later than the Q3 2026 start previously planned. With $13.1 million of cash at June 30 and substantial doubt about continuing as a going concern, the case depends on new funding or a partner.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Phase 2 starts in Parkinson's disease
Does Gain submit the Phase 2 protocol and keep a Q1 2027 start?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Rexaceract's 12-month Parkinson's signal needs new funding before Phase 2 can deliver
Parkinson's GCase modulator with Phase 1b durability data racing a Q2 2027 cash wall — survival to Phase 2 proof-of-concept is the single condition
GCase modulator with Phase 1b biomarker signals enters Phase 2 — cash runway tests whether it survives to data
GT-02287's Phase 2 in GBA1-linked Parkinson's hinges on whether biomarker signals translate to registrational clinical efficacy
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Rexaceract
Disease areas: Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
8 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.